Biocytogen Pharmaceuticals Co., Ltd. signed a non-exclusive license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s RenLite platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain, and other biological therapeutics for an unlimited number of drug targets and indications.

Yuelei Shen, founder, chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”

RenLite is a member of Biocytogen’s fully human antibody RenMice family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate.

The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.